Literature DB >> 1677751

Gender effects and central opioid analgesia.

Karen L Kepler1, Kelly M Standifer, Dennis Paul, Benjamin Kest, Gavril W Pasternak, Richard J Bodnar.   

Abstract

Central morphine analgesia is significantly greater in male than in female rats. Since mu and delta opioid receptor subtypes have been implicated in supraspinal analgesia, the present study evaluated whether gender or adult gonadectomy altered (a) analgesia on the tail-flick and jump tests following central administration of the mu-selective agonist, [D-Ala2, Me-Phe4, Gly(ol)5] enkephalin (DAMGO) and the delta-selective agonist, [D-Ser2,Leu5] enkephalin-Thr6 (DSLET) and (b) mu1, mu2 and delta opioid receptor binding. Sham-operated male rats displayed significantly greater magnitudes of peak and total analgesia than sham-operated females on the tail-flick test following DAMGO, but not DSLET. Gender differences were not observed for DAMGO and DSLET analgesia on the jump test. Gonadectomy failed to consistently affect either DAMGO or DSLET analgesia. Regression analyses failed to reflect significant shifts in the dose-response functions for either agonist on either measure. Gender differences were not observed for mu1, mu2, or delta binding in hypothalamus or cortex. These data are compared with analgesic responses sensitive to gender differences.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677751     DOI: 10.1016/0304-3959(91)90168-W

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  33 in total

1.  Contribution of GIRK2-mediated postsynaptic signaling to opiate and alpha 2-adrenergic analgesia and analgesic sex differences.

Authors:  Igor Mitrovic; Marta Margeta-Mitrovic; Semon Bader; Markus Stoffel; Lily Y Jan; Allan I Basbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-20       Impact factor: 11.205

2.  Neonatal androgen-dependent sex differences in lumbar spinal cord dopamine concentrations and the number of A11 diencephalospinal dopamine neurons.

Authors:  Samuel S Pappas; Chelsea T Tiernan; Bahareh Behrouz; Cynthia L Jordan; S Marc Breedlove; John L Goudreau; Keith J Lookingland
Journal:  J Comp Neurol       Date:  2010-07-01       Impact factor: 3.215

3.  PAG mu opioid receptor activation underlies sex differences in morphine antinociception.

Authors:  Scott A Bernal; Michael M Morgan; Rebecca M Craft
Journal:  Behav Brain Res       Date:  2006-11-21       Impact factor: 3.332

4.  Dissociation between sex differences in the immunological, behavioral, and physiological effects of kappa- and delta-opioids in Fischer rats.

Authors:  Jay C Elliott; Mitchell J Picker; Andrew J Sparrow; Donald T Lysle
Journal:  Psychopharmacology (Berl)       Date:  2006-01-06       Impact factor: 4.530

5.  Identification of a sex-specific quantitative trait locus mediating nonopioid stress-induced analgesia in female mice.

Authors:  J S Mogil; S P Richards; L A O'Toole; M L Helms; S R Mitchell; B Kest; J K Belknap
Journal:  J Neurosci       Date:  1997-10-15       Impact factor: 6.167

6.  Intraoperative clonidine enhances postoperative morphine patient-controlled analgesia.

Authors:  M F De Kock; G Pichon; J L Scholtes
Journal:  Can J Anaesth       Date:  1992-07       Impact factor: 5.063

7.  Persistent pain model reveals sex difference in morphine potency.

Authors:  Xiaoya Wang; Richard J Traub; Anne Z Murphy
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-02-23       Impact factor: 3.619

Review 8.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 9.  Somatic symptom reporting in women and men.

Authors:  A J Barsky; H M Peekna; J F Borus
Journal:  J Gen Intern Med       Date:  2001-04       Impact factor: 5.128

10.  Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach.

Authors:  Monica Rodriguez; M Angeles Carlos; Ignacio Ortega; Elena Suarez; Rosario Calvo; John C Lukas
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.